Elutia (ELUT) Stock Price

Elutia Price

NASDAQ·CLOSED
0.85USD-0.03 (-3.58 %)
Market closed

Revenue at Elutia has contracted by 15.2% per year over the past 7 years to 12.29 M USD. For Elutia, the net margin of 434.2% is up versus -52.4% a few years ago. The consensus 12-month price target for Elutia is 3.57 USD, about 320.0% above where the stock trades today. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 68% above its 52-week low.

Elutia stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Elutia over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Elutia stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Elutia's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Elutia Stock Price History
DateElutia Price
8/7/20260.85 USD
8/6/20260.88 USD
8/5/20260.87 USD
8/4/20260.88 USD
8/3/20260.87 USD
7/31/20260.86 USD
7/30/20260.90 USD
7/29/20260.88 USD
7/28/20260.92 USD
7/27/20260.91 USD
7/23/20260.93 USD
7/22/20260.93 USD
7/21/20260.95 USD
7/20/20260.93 USD
7/17/20260.95 USD
7/16/20260.95 USD
7/15/20260.96 USD
7/14/20260.91 USD
7/13/20260.97 USD
7/10/20260.96 USD
7/9/20260.97 USD
7/8/20260.97 USD
7/7/20260.96 USD
7/6/20260.93 USD
7/2/20260.93 USD
7/1/20260.94 USD
6/30/20260.98 USD
6/29/20260.96 USD
6/26/20261.00 USD
6/25/20260.95 USD
6/24/20260.98 USD
6/23/20261.03 USD
6/22/20261.07 USD
6/18/20261.06 USD
6/17/20260.99 USD
6/16/20260.95 USD
6/15/20260.97 USD
6/12/20260.96 USD
6/11/20260.96 USD
6/10/20261.04 USD
6/9/20260.97 USD
6/8/20260.99 USD
6/5/20261.00 USD
6/4/20261.05 USD
6/3/20260.99 USD
6/2/20261.04 USD
6/1/20261.06 USD
5/29/20261.16 USD
5/28/20261.12 USD
5/27/20261.13 USD
5/26/20261.14 USD
5/22/20261.16 USD
5/21/20261.20 USD
5/20/20261.18 USD
5/19/20261.12 USD
5/18/20261.10 USD
5/15/20261.03 USD
5/14/20261.04 USD
5/13/20261.05 USD
5/12/20261.05 USD
5/11/20261.06 USD
5/8/20261.01 USD
5/7/20261.00 USD
5/6/20261.02 USD
5/5/20260.98 USD
5/4/20261.01 USD
5/1/20261.01 USD
4/30/20261.02 USD
4/29/20261.00 USD
4/28/20261.00 USD
4/27/20261.02 USD
4/24/20261.07 USD
4/23/20261.11 USD
4/22/20261.15 USD
4/21/20261.17 USD
4/20/20261.12 USD
4/17/20261.15 USD
4/16/20261.17 USD
4/15/20261.17 USD
4/14/20261.14 USD
4/13/20261.10 USD
4/10/20261.13 USD
4/9/20261.13 USD
4/8/20261.14 USD
4/7/20261.16 USD
4/6/20261.16 USD
4/2/20261.17 USD
4/1/20261.09 USD
3/31/20261.05 USD
3/30/20261.05 USD
3/27/20261.07 USD
3/26/20261.07 USD
3/25/20261.12 USD
3/24/20261.06 USD
3/23/20261.11 USD
3/20/20261.10 USD
3/19/20261.05 USD
3/18/20261.08 USD
3/17/20261.09 USD
3/16/20261.07 USD
3/13/20261.08 USD
3/12/20261.15 USD
3/11/20261.09 USD
3/10/20261.09 USD
3/9/20261.17 USD
3/6/20261.09 USD
3/5/20261.11 USD
3/4/20261.19 USD
3/3/20261.22 USD
3/2/20261.14 USD
2/27/20261.15 USD
2/26/20261.15 USD
2/25/20261.09 USD
2/24/20261.09 USD
2/23/20261.12 USD
2/20/20261.08 USD
2/19/20261.12 USD
2/18/20261.20 USD
2/17/20261.15 USD
2/13/20261.05 USD
2/12/20260.95 USD
2/11/20260.90 USD
2/10/20260.95 USD
2/9/20260.95 USD
2/6/20260.99 USD
2/5/20260.94 USD
2/4/20260.99 USD
2/3/20260.98 USD
2/2/20261.02 USD
1/30/20261.05 USD
1/29/20261.05 USD
1/28/20261.05 USD
1/27/20261.00 USD
1/26/20260.94 USD
1/23/20260.95 USD
1/22/20261.01 USD
1/21/20260.92 USD
1/20/20260.84 USD
1/16/20260.82 USD
1/15/20260.81 USD
1/14/20260.84 USD
1/13/20260.88 USD
1/12/20260.69 USD
1/9/20260.72 USD
1/8/20260.69 USD
1/7/20260.67 USD
1/6/20260.63 USD
1/5/20260.61 USD
1/2/20260.64 USD
12/31/20250.69 USD
12/30/20250.58 USD
12/29/20250.54 USD
12/26/20250.54 USD
12/24/20250.56 USD
12/23/20250.54 USD
12/22/20250.55 USD
12/19/20250.59 USD
12/18/20250.54 USD
12/17/20250.51 USD
12/16/20250.55 USD
12/15/20250.67 USD
12/12/20250.70 USD
12/11/20250.70 USD
12/10/20250.70 USD
12/9/20250.70 USD
12/8/20250.68 USD
12/5/20250.69 USD
12/4/20250.69 USD
12/3/20250.65 USD
12/2/20250.65 USD
12/1/20250.66 USD
11/28/20250.61 USD
11/26/20250.67 USD
11/25/20250.62 USD
11/24/20250.60 USD
11/21/20250.59 USD
11/20/20250.62 USD
11/19/20250.66 USD
11/18/20250.70 USD
11/17/20250.73 USD
11/14/20250.75 USD
11/13/20250.74 USD
11/12/20250.74 USD
11/11/20250.82 USD
11/10/20250.86 USD
11/7/20250.90 USD
11/6/20250.94 USD
11/5/20250.96 USD
11/4/20250.92 USD
11/3/20250.94 USD
10/31/20250.91 USD
10/30/20250.91 USD
10/29/20250.90 USD
10/28/20250.90 USD
10/27/20250.90 USD
10/24/20250.90 USD
10/23/20250.91 USD
10/22/20250.90 USD
10/21/20250.90 USD
10/20/20250.90 USD
10/17/20250.89 USD
10/16/20250.90 USD
10/15/20250.89 USD
10/14/20250.89 USD
10/13/20250.90 USD
10/10/20250.89 USD
10/9/20250.88 USD
10/8/20250.89 USD
10/7/20250.88 USD
10/6/20250.88 USD
10/3/20250.88 USD
10/2/20250.90 USD
10/1/20250.89 USD
9/30/20250.89 USD
9/29/20250.93 USD
9/26/20250.99 USD
9/25/20251.03 USD
9/24/20251.05 USD
9/23/20251.06 USD
9/22/20251.11 USD
9/19/20251.09 USD
9/18/20251.08 USD
9/17/20251.13 USD
9/16/20251.18 USD
9/15/20251.22 USD
9/12/20251.28 USD
9/11/20251.31 USD
9/10/20251.36 USD
9/9/20251.48 USD
9/8/20251.88 USD
9/5/20251.88 USD
9/4/20252.01 USD
9/3/20251.99 USD
9/2/20252.17 USD
8/29/20252.28 USD
8/28/20252.33 USD
8/27/20252.21 USD
8/26/20252.40 USD
8/25/20252.39 USD
8/22/20252.09 USD
8/21/20252.20 USD
8/20/20252.12 USD
8/19/20252.02 USD
8/18/20252.02 USD
8/15/20252.02 USD
8/14/20252.15 USD
8/13/20252.16 USD
8/12/20251.99 USD
8/11/20251.97 USD
Access this data via the Eulerpool API
Get Free API Key

Elutia Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
42.68 M USD
-16.17 M USD
-21.83 M USD
Jan 1, 2021
47.39 M USD
-19.45 M USD
-24.83 M USD
Jan 1, 2022
23.85 M USD
-31.03 M USD
-32.90 M USD
Jan 1, 2023
24.75 M USD
-35.43 M USD
-37.66 M USD
Jan 1, 2024
24.38 M USD
-49.34 M USD
-53.95 M USD
Jan 1, 2025
12.29 M USD
-18.41 M USD
53.38 M USD
Jan 1, 2026 (e)
12.00 M USD
-10.59 M USD
-25.62 M USD
Jan 1, 2027 (e)
13.10 M USD
-11.56 M USD
-22.20 M USD

Elutia Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 10, 2026, 1:13 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201820192020202120222023202420252026e2027e
39.0042.0042.0047.0023.0024.0024.0012.0012.0013.00
–7.69–11.90-51.064.35–-50.00–8.33
38.4645.2447.6240.4347.8345.8341.6750.0050.0050.00
15.0019.0020.0019.0011.0011.0010.006.006.006.50
-8.00-8.00-16.00-19.00-31.00-35.00-49.00-18.00-10.00-11.00
-20.51-19.05-38.10-40.43-134.78-145.83-204.17-150.00-83.33-84.62
-11.00-11.00-21.00-24.00-32.00-37.00-53.0053.00-25.00-22.00
––90.9114.2933.3315.6343.24-200.00-147.17-12.00
1.001.009.0011.0814.4723.2034.8547.2447.2447.24
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Elutia generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Elutia retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Elutia's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Elutia has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Elutia's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Elutia stock margins

The Elutia margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Elutia. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Elutia.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
48.17 %
-37.88 %
-51.13 %
Jan 1, 2021
40.14 %
-41.05 %
-52.40 %
Jan 1, 2022
48.80 %
-130.11 %
-137.94 %
Jan 1, 2023
44.67 %
-143.16 %
-152.18 %
Jan 1, 2024
43.93 %
-202.43 %
-221.33 %
Jan 1, 2025
53.66 %
-149.78 %
434.23 %
Jan 1, 2026 (e)
53.66 %
-88.21 %
-213.50 %
Jan 1, 2027 (e)
53.66 %
-88.21 %
-169.50 %

Elutia Stock Revenue, EBIT, Earnings per Share

The Elutia earnings per share therefore indicates how much revenue Elutia has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
4.74 USD
-1.80 USD
-2.43 USD
Jan 1, 2021
4.28 USD
-1.76 USD
-2.24 USD
Jan 1, 2022
1.65 USD
-2.14 USD
-2.27 USD
Jan 1, 2023
1.07 USD
-1.53 USD
-1.62 USD
Jan 1, 2024
0.70 USD
-1.42 USD
-1.55 USD
Jan 1, 2025
0.26 USD
-0.39 USD
1.13 USD
Jan 1, 2026 (e)
0.28 USD
-0.22 USD
-0.60 USD
Jan 1, 2027 (e)
0.31 USD
-0.24 USD
-0.52 USD

Elutia business model & stock analysis

Aziyo Biologics Inc.: A history of innovation

Elutia SWOT Analysis

Strengths

Aziyo Biologics Inc. possesses several key strengths that contribute to its success in the biologics industry. These strengths include:

  • Strong market position and brand recognition
  • Advanced and innovative product portfolio
  • In-depth knowledge and expertise in biologics development
  • Established distribution networks
  • Strong financial performance

Weaknesses

Despite its overall success, Aziyo Biologics Inc. faces certain weaknesses that could hinder its growth and competitiveness. These weaknesses include:

  • Limited geographical presence
  • Reliance on key suppliers
  • High production costs
  • Regulatory challenges and compliance requirements
  • Limited diversification of product portfolio

Opportunities

Aziyo Biologics Inc. has several opportunities for further growth and expansion. These opportunities include:

  • Increasing demand for biologics in the healthcare industry
  • Expanding into new markets and geographical regions
  • Collaborating with healthcare organizations and research institutions
  • Developing new and innovative biologic products
  • Investing in research and development for potential breakthroughs

Threats

Aziyo Biologics Inc. faces various threats that could potentially disrupt its operations and market position. These threats include:

  • Intense competition from existing and emerging biologics companies
  • Stringent regulations and approvals required for biologics
  • Potential risks associated with product quality and safety
  • Economic downturns and fluctuations in healthcare spending
  • Technological advancements that could render current products obsolete

Elutia Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Elutia Employees
Details
Date
Elutia Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Elutia Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Elutia historical P/E ratio, EBIT multiple, and P/S ratio

Elutia annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Elutia shares outstanding

The number of shares of Elutia was 47.24 M in 2025. This indicates how many shares Elutia is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
9.00 M Stocks
Jan 1, 2021
11.08 M Stocks
Jan 1, 2022
14.47 M Stocks
Jan 1, 2023
23.20 M Stocks
Jan 1, 2024
34.85 M Stocks
Jan 1, 2025
47.24 M Stocks
Jan 1, 2026 (e)
47.24 M Stocks
Jan 1, 2027 (e)
47.24 M Stocks

Current Elutia forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
87.50 % (7)
Hold
12.50 % (1)
Sell
0.00 % (0)
12M Price Target
3.57
Last Price
0.85
Currency
USD
12M Return Potential
320.00 %
LTM Return
0 %

Elutia Analyst Rating Actions

DateFirmActionRatingReliability
9/10/2025
Lake Street
Lake Street
MaintainedBuy–
5/9/2025
Lake Street
Lake Street
MaintainedBuy–
3/7/2025
Cantor Fitzgerald
Cantor Fitzgerald
MaintainedOverweight44
11/15/2024
Cantor Fitzgerald
Cantor Fitzgerald
MaintainedOverweight44
9/6/2024
Cantor Fitzgerald
Cantor Fitzgerald
MaintainedOverweight44
8/8/2024
Cantor Fitzgerald
Cantor Fitzgerald
MaintainedOverweight44
6/21/2024
Lake Street
Lake Street
MaintainedBuy–
6/20/2024
Cantor Fitzgerald
Cantor Fitzgerald
MaintainedOverweight44
6/18/2024
Cantor Fitzgerald
Cantor Fitzgerald
MaintainedOverweight44
5/10/2024
Cantor Fitzgerald
Cantor Fitzgerald
MaintainedOverweight44

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Elutia Earnings Calls

2025

Elutia Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/13/2026-0.15USD-2.96 MUSD-2026 Q2
5/14/2026-0.15USD-3.06 MUSD-2026 Q1
3/11/2026-0.14USD-3.37 MUSD-2025 Q4
11/14/2024-0.45USD-6.73 MUSD-2024 Q3
5/8/2024-0.33USD-6.43 MUSD-2024 Q1
3/20/2024-0.33USD-6.43 MUSD-2023 Q4

EESG©

Eulerpool ESG Scorecard© for the Elutia stock

0/100
0
Environment
1
Social
0
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging—
Hazardous substances
Fuel consumption and efficiency—
Water consumption and efficiency—
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety—
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting—
Stakeholder Engagement—
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Elutia shareholder structure

% Name
4.73424%
AIGH Capital Management, LLC.
AIGH Capital Management, LLC.
2.64988%
Perkins Capital Management, Inc.
Perkins Capital Management, Inc.
0.86433%
Ferguson (Matthew B)
Ferguson (Matthew B)
0.79294%
Mills (Charles Randal)
Mills (Charles Randal)
0.21870%
Williams (Michelle LeRoux)
Williams (Michelle LeRoux)
0.14637%
Neels (Guido J)
Neels (Guido J)

Elutia Beneficial Ownership Filings (SEC 13D/G)

Free Float
79.9%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
26.10%
W. Matthew Zuga
W. Matthew Zuga
SEC ↗
13.00%
Kevin Rakin
Kevin Rakin
SEC ↗
11.50%
HighCape Partners GP II, L.P.
HighCape Partners GP II, L.P.
SEC ↗
11.30%
HighCape Partners QP II, L.P.
HighCape Partners QP II, L.P.
SEC ↗
9.99%
Nantahala Capital Management, LLC
Nantahala Capital Management, LLC
SEC ↗
7.60%
Orin Hirschman
Orin Hirschman
SEC ↗
6.30%
Knollwood Investment Advisory, LLC
Knollwood Investment Advisory, LLC
SEC ↗
5.90%
SilverArc Capital Management, LLC
SilverArc Capital Management, LLC
SEC ↗
5.53%
Devesh Gandhi
Devesh Gandhi
SEC ↗
3.18%
Alyeska Investment Group, L.P.
Alyeska Investment Group, L.P.
SEC ↗

Elutia Executives and Management Board

8 members · avg. age 59 · 38 % women

CM

Dr. C. Randal Mills (53)

President, Chief Executive Officer, Director · since 2015

4.54 M USD

Management

MF

Mr. Matthew Ferguson (57)

Chief Financial Officer

1.81 M USD
MW

Dr. Michelle Williams (51)

Chief Scientific Officer

1.60 M USD

Board of Directors

KR

Mr. Kevin Rakin (64)

Lead Independent Chairman of the Board · since 2015

321,500.00 USD
BM

Ms. Brigid Makes (68)

Independent Director

161,000.00 USD
MJ

Ms. Maybelle Jordan (59)

Independent Director

141,000.00 USD
DC

Mr. David Colpman (64)

Independent Director

138,500.00 USD
WZ

Mr. W. Matthew Zuga (59)

Independent Director

121,000.00 USD

Frequently asked questions about Elutia

Aziyo Biologics Inc's business model revolves around developing and commercializing regenerative medical solutions to improve patient outcomes. The company focuses on supplying uniquely processed human tissue grafts and innovative biologics for use in various medical procedures. Aziyo Biologics Inc aims to enhance the body's natural healing processes by delivering high-quality, safe, and effective regenerative medicine products. The company's dedication to research, clinical innovation, and collaboration with healthcare professionals enables them to address unmet needs in the fields of cardiovascular, orthopedic, and other surgical specialties. With its patient-centric approach, Aziyo Biologics Inc strives to provide advanced regenerative solutions to improve the quality of life for individuals worldwide.

Aziyo Biologics Inc primarily operates in the healthcare and biotechnology industries.

The main competitors of Aziyo Biologics Inc in the market include Medtronic, Johnson & Johnson, Baxter International, and Zimmer Biomet. These companies also operate in the biologics and medical device industry, providing similar products and solutions. However, Aziyo Biologics Inc differentiates itself through its focus on the development and commercialization of regenerative medicine products, such as cardiovascular and orthopedic tissues. Aziyo Biologics Inc continues to strive for innovation and market presence, driving competition within the industry.

Aziyo Biologics Inc is a leading regenerative medicine company based in the United States. Established in 2015, the company specializes in the development and commercialization of innovative biologic products. Aziyo Biologics has a strong focus on creating solutions for surgical procedures within the fields of cardiovascular, orthopedics, and other medical specialties. With a commitment to improving patient outcomes, Aziyo Biologics combines cutting-edge science, advanced manufacturing techniques, and clinical expertise to deliver high-quality tissue products. The company's rich history of research, development, and collaboration with healthcare professionals has positioned it as a trusted provider in the regenerative medicine space.

Aziyo Biologics Inc has achieved several significant milestones. Firstly, the company successfully completed its initial public offering (IPO) in March 2021, raising substantial funds to support its growth and business operations. Additionally, Aziyo Biologics has expanded its product portfolio by launching innovative regenerative medical solutions, including CanGaroo Envelope, a product designed to support cardiac implantable electronic devices. Furthermore, the company has established strategic partnerships with renowned healthcare organizations to enhance its market presence and broaden its customer base. Aziyo Biologics Inc continues to demonstrate its commitment to advancing the field of regenerative medicine through these notable achievements.

Aziyo Biologics Inc is primarily present in the United States.

Aziyo Biologics Inc represents a strong commitment to advancing the field of regenerative medicine and improving patient outcomes. Their corporate philosophy revolves around innovation, excellence, and collaboration. With a focus on developing and delivering high-quality tissue products and solutions, Aziyo Biologics aims to meet the diverse needs of the medical community. By leveraging their expertise, cutting-edge technology, and dedication to quality, the company strives to make a positive impact on the lives of patients worldwide. Aziyo Biologics also emphasizes transparency, integrity, and ethical practices, ensuring the utmost trust and confidence among their stakeholders.

Analysts currently set an average price target of 3.57 USD for the Elutia stock (median: 3.57 USD), implying +320.0 % versus the latest price. The consensus is based on 8 analyst ratings.

Elutia Analyst Price Targets 2026

8 analysts currently rate the Elutia stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Elutia to generate revenue of 12.00 M USD and earnings per share of -0.54 USD.

Elutia Analyst Price Targets 2026

Converted at the current exchange rate, the Elutia share trades at 0.74 EUR (0.85 USD).

The Elutia share (ELUT) is listed on 1 stock exchanges, including: NASDAQ (AZYO).

Aziyo Biologics Inc is a company specializing in the development and marketing of cardiovascular and regenerative tissue products. It is headquartered in Silver Spring, Maryland, and has been in the market since 2015. The business model of Aziyo Biologics includes several divisions, including cardiovascular products, regenerative tissue technologies, and tissue banking services. The company's key products include the CanGaroo® PFO closure system, the BioBridge® vascular graft system, and the ViBone® regeneration product. The CanGaroo® PFO closure system is an innovative product designed specifically for closing defects in the interatrial septum. It is made from porcine tissue materials and is a safe and effective alternative to the transcutaneous PFO closure method. The BioBridge® vascular graft system is another important product of Aziyo Biologics. It is a synthetic vascular implant made from a biocompatible material and is an ideal choice for patients with spinal cord injuries or severe vascular complications. ViBone® is a regenerative product derived from clean donor bone and represents a natural source of growth factors. It is commonly used in repairing muscle and bone damage and is a key component of Aziyo's regenerative tissue solutions. To develop and distribute these products, Aziyo Biologics works closely with Aziyo Biologics Australia, a subsidiary specializing in the development of regenerative muscle and bone tissue. Additionally, the company operates a range of tissue banking services that allow patients to access donor tissue and improve their health. Aziyo Biologics' tissue banking services include preservation, processing, preparation, and storage of blood, bone, and other biological materials. These materials are then supplied to hospitals and medical facilities to support patients with injuries or illnesses. Aziyo Biologics' business model is based on creating high-quality tissue solutions and building long-term relationships with medical and health-related institutions. The company also conducts a range of research and development programs to create innovative new products and strengthen its presence in the market. Overall, Aziyo Biologics has established itself as a key player in the field of regenerative medicine and offers a wide range of products and services to help patients around the world. With a strong commitment to innovation and quality, the company has laid a solid foundation for future growth and progress.

The expected revenue of Elutia is 12.00 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Elutia is -25.62 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Elutia is currently -1.57. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Elutia stock.

The price-to-sales ratio (P/S) of Elutia is currently 3.35. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Elutia stock.

The Eulerpool Quality Score for Elutia is 2/10.

The ISIN of Elutia is US05479K1060. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Elutia is ELUT. The ticker symbol is used to trade Elutia shares on the stock exchange.

Elutia paid dividends every year for the past 0 years.

Elutia is assigned to the 'Health' sector.

The dividends of Elutia are distributed in USD.

All fundamentals and in-depth analysis of Elutia

Our stock analysis for Elutia stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Elutia. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Elutia Stock
Elutia Revenue→
Elutia Stock
Elutia Net Income→
Elutia Stock
Elutia P/E→
Elutia Stock
Elutia P/S→
Elutia Stock
Elutia EBIT→
Elutia Stock
Elutia Dividend→
Elutia Stock
Elutia Directors Dealings→
Elutia Stock
Elutia Stocks→
Elutia Stock
Elutia Market capitalization→
Elutia Stock
Elutia Debt→
Elutia Stock
Elutia Liabilities→
Elutia Stock
Elutia Equity→
Elutia Stock
Elutia AAQS→
Elutia Stock
Elutia Employees→
Elutia Stock
Elutia ROE→
Elutia Stock
Elutia ROA→
Elutia Stock
Elutia ROCE→
Elutia Stock
Elutia News→
Elutia Stock
Elutia Analyst Price Targets→

Health Stocks

EM Systems CoEloxx PharmaceuticalsEmbectaElite PharmaceuticalsEmbracing Future HoldingsElicio TherapeuticsEmcure PharmaceuticalsElicera TherapeuticsEmeisEli Lilly and CoEmergency Assistance Japan CoElexxionAll Stocks A–Z →